Cardiovascular prevention in peri- and postmenopausal women

Кардиоваскулярная терапия и профилактика

卷:10

V. B. Mychka¹  M. Yu. Kirillova¹  N. A. Voychenko²  I. V. Kuznetsova³  S. N. Tolstov⁴ 

[1] A.L. Myasnikov Research Institute of Clinical Cardiology, Russian Cardiology Scientific and Clinical Complex;

[2] I.M. Sechenov First Moscow State Medical University;

[3] Russian Medical Academy of Post-Diploma Education;

[4] Yu.Ya. Gordeev First Clinical Hospital;

关键词: metabolic syndrome;    menopause;    renin-angiotensin-aldosterone system;    arterial hypertension;    obesity;    hormone replacement therapy;    drospirenone;   

DOI  :  10.15829/1728-8800-2011-3-123-130

来源: DOAJ

【 摘 要 】

The adverse consequences of estrogen deficiency in postmenopause include cardiovascular disease (CVD), which affects not only women’s quality of life, but also their life expectancy. Before premenopause, women have significantly lower risk of arterial hypertension than men of the same age. However, in people aged over 50, AH is more prevalent among women. Currently, most experts regard hormone replacement therapy (HRT) in peri- and postmenopausal women as pathogenetic, since it facilitates the adaptation of the female organism to the new metabolic state, with reduced ovarian function. Drospirenone, as a part of HRT, reduces CVD risk in postmenopausal women with climacteric disturbances.

【 授权许可】

Unknown